Treatment of hepatorenal syndromes (HRSs) is currently based on vasopressin analogs. The aim of this pilot study was to evaluate the efficacy and safety of noradrenalin (NA) in the treatment of type 1 HRS. Between 1998 and 2000, 12 consecutive patients with type 1 HRS (7 men, 5 women; mean age, 54 ؎ 11 years; mean Child-Pugh score, 11.3 ؎ 1.7) were treated with intravenous NA (0.5-3 mg/h), in combination with intravenous albumin and furosemide. NA was given for 10 ؎ 3 days, at a mean dose of 0.8 ؎ 0.3 mg/h. Reversal of HRS was observed in 10 of 12 patients (83%; 95% confidence interval, 52%-98%) after a median of 7 days (range, 5-10 days). Serum creatinine levels fell from 358 ؎ 161 to 145 ؎ 78 mol/L (P < .001), creatinine clearance rose from 13 ؎ 9 to 40 ؎ 15 mL/min (P ‫؍‬ . H epatorenal syndrome (HRS) is a frequent and major complication of end-stage cirrhosis. It is considered as a functional renal failure caused by marked renal vasoconstriction, related to peripheral (mainly splanchnic) arterial vasodilation. 1 Type 1 HRS usually occurs in patients with end-stage liver disease and shows a poor prognosis. The median survival time is about 10 days. It is defined as rapidly progressive renal failure with a 50% reduction in initial creatinine clearance to below 20 mL/min within 15 days. 2 Type 2 HRS occurs instead in patients with refractory ascites and is characterized by moderate and more stable impairment of renal function. Liver transplantation is the only treatment to improve survival in patients with type I HRS 3 ; however, because of the very poor prognosis of type 1 HRS and because of organ shortage, a donor is usually not found quickly enough to avoid death. HRS management thus focuses on improving renal function and thereby extending survival pending liver transplantation. This has recently been addressed by assessing the effects of vasoconstrictors that, combined with plasma expanders, restore the collapse of systemic vascular resistances (SVRs) underlying HRS. 1,4-9 Thus, vasopressin analogs such as ornipressin 4-6 and terlipressin 7-9 improve renal perfusion and glomerular filtration in patients with HRS by inducing vasoconstriction of the splanchnic circulation.Noradrenalin (NA) is a catecholamine with predominantly ␣-adrenergic activity. Given its vasoconstricting effects in venous and arterial systems, and its limited action on the myocardium, it is currently the drug of choice for vasoplegic shock. These pharmacologic properties suggest that NA might also counteract the collapse in SVRs leading to HRS. After a case report of successful treatment of HRS with a combination of NA and dopamine, 10 we conducted a pilot study to Abbreviations: HRS, hepatorenal syndrome; SVR, systemic vascular resistance; NA, noradrenalin; CVP, central venous pressure; MAP, mean arterial pressure. From the

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

We believe that optimal management of these patients with chronic spontaneous encephalopathy is liver transplantation.